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. Four patients 33% achieved an overall remission OR . The time from diagnosis to GO infusion was signi cantly longer in patients with OR than in patients with no remission NR 1747 vs. 501 days, respectively ; P 0.01 . The number of karyotype abnormalities before GO infusion was signi cantly greater in NR patients 9.5 than in OR patients 0.5 ; P 0.03 . Monocyte counts in the bone marrow before GO therapy were signi cantly lower in OR than in NR patients 100/ µL vs. 1080/ L, respectively ; P 0.048 . In a multivariate analysis, monocyte count was signi cantly associated with overall survival P 0.005 . CD14 expression in OR patients was lower than in NR patients, with the exception of 4 patients whose French-American-British subtypes were M4 or M5 OR, 0.3% ; NR, 2.5% ; P 0.04 . NR was noted in all 6 patients who underwent allogeneic stem cell transplantation before and/or after GO infusion. Patients showing good sensitivity to conventional chemotherapy with good survival after diagnosis tend to be sensitive to GO as well. A low monocyte count in the bone marrow at infusion of GO might indicate improved ef cacy of GO therapy. Further investigation is warranted for establishing appropriate patient selection and for clarifying ef cient conditions for GO therapy.
In Japan, GO has been approved as a monotherapy treatment for relapsed or refractory CD33-positive AML since 2005. However, GO monotherapy has had limited efficacy 2 .
Similar to non-Japanese studies, the overall remission OR rate for GO monotherapy has been reported as 30% in a Japanese phase II study 2, 3 . The following predictive factors affecting the clinical outcome of GO therapy have been identified in previous studies :
P-glycoprotein activity and expression 1, 4 , multi-drug resistance protein ATP-binding cassette, sub-family C, member 4 , white blood cell WBC count at the start of GO therapy 5 , CD33-antigen loads in peripheral blood PB 6 , duration of initial complete remission 7 , and cytogenetic risk 7 . However, it is dif cult to predict the outcome of GO therapy based on these factors alone. Additionally, there have been no reports regarding predictive factors that affect clinical outcomes of GO therapy among Japanese patients. In our study, we retrospectively evaluated the use of GO in 12 patients treated at our hospital and analyzed the pretreatment factors that affected their clinical outcome.
Patients and Methods

Patients
Twelve patients with relapsed/refractory de novo acute leukemia who were treated with GO at our hospital between September 2007 and August 2009 were included in this study. Cytogenetic analyses were performed on bone marrow BM samples of all patients using the G-banding method at the time of diagnosis of leukemia and before GO infusion.
Cytogenetic risk was categorized according to the Southwest Oncology Group SWOG 9 and Medical Research Council MRC 10 classification for cytogenetic risk. Cell surface expression of CD33 and CD14 on the leukemic blasts in the pretreatment BM samples was determined by ow cytometry in all patients.
Ef cacy measures
Ef cacy measures were categorized into the following 3 groups : complete remission CR , CR with incomplete platelet recovery CRp , and no remission NR 7 . CR was de ned as :
I the absence of leukemic blasts in PB ; II no more than 5% leukemic blasts in the BM, as measured by BM aspiration or biopsy samples ; III PB counts with hemoglobin concentration ≥ 9 g/dL, absolute neutrophil count ≥ 1500/ L, and platelet count ≥ 100,000/ L ; and IV red blood cell transfusion independence ≥ 2 weeks with platelet transfusion independence ≥ 1 week. CRp was similarly de ned, but CRp platelet counts were <100,000/ L. Patients who did not satisfy the criteria for either CR or CRp were categorized as NR. OR included both CR and CRp. Determination of remission status was evaluated from 15 days to 70 days after the rst administration of GO.
Overall survival OS was de ned as the time from the rst GO infusion until death.
Event-free survival was defined as the time from the first GO infusion until death or relapse of leukemia. Duration of initial complete remission CR1 of leukemia was de ned as the time from diagnosis of CR1 to the rst relapse of leukemia.
Pretreatment factors
Patients were divided into 2 groups based on the GO ef cacy measures, i.e., the OR and NR groups. In a univariate analysis, various factors mentioned below were compared between the 2 groups at the time of diagnosis of leukemia, before the rst GO infusion, and at the rst GO infusion. 
Safety measures
Adverse events were graded using the Common Terminology Criteria for Adverse Events, version 3.0. WBC counts from day 1 to day 14 after the rst GO infusion were compared between the 2 groups using the Wilcoxon test. Unmeasured values of WBC counts were substituted by interpolated values derived from the adjacent values using linear interpolation.
Statistical analyses
Survival curves were calculated according to the Kaplan-Meier method and compared using the log-rank test. Univariate analysis was performed using the Wilcoxon test and chi-square analysis, while multivariate analysis was performed using the Cox regression analysis.
Statistical analyses were performed using the software program, KyPlot, version 5.0 KyensLab Co. Ltd., Tokyo, Japan . In all tests, P 0.05 was considered signi cant.
Results
Patient characteristics
We evaluated 12 patients in this study. The median age was 56 years range, 27-85 years , the male : female ratio was 6 6, and the mean observation time was 200 days range, days . The patients leukemic status and laboratory data are presented in Tables 1 and 2 .
Patient characteristics are listed according to the categories of GO ef cacy in Table 3 .
Feasibility and treatment outcomes
All 12 patients received the first dose of GO as a monotherapy, following which 8 patients received 1 course and 1 patient received 3 courses of GO 1 course was de ned as 2 doses of GO . For the patients who received 2 or more doses, there was a median gap of 14 days range, 9-54 days between the rst and second doses. The median initial dose was 8.1 mg/m 2 range, 5.8-9.1 mg/m 2 . CR, CRp, OR, and NR were observed in 2 17% , 2 17% , 4 33% , and 8 patients 68% , respectively Table 1 .
Pretreatment factors according to ef cacy measures
The pretreatment factors listed above were compared between the OR and NR groups Table 4 . No clinical factors at the time of diagnosis of leukemia were signi cantly associated with the clinical outcome, however a number of signi cant differences between the 2 groups were observed for factors before or at GO infusion. The duration of CR1 and the duration between diagnosis of leukemia and the rst GO infusion were signi cantly longer in OR patients. The ECOG performance status was significantly greater in NR patients compared to OR patients P 0.03 . In addition, the number of karyotype abnormalities before GO infusion was signi cantly greater in NR patients than in OR patients 9.5 vs.
0.5, respectively ; P 0.03 , and the cytogenetic risk was also signi cantly different between OR and NR patients, according to both the SWOG P 0.01 and MRC P 0.049 classi cation systems. sion of GO tended to be lower than in NR patients OR, 14.0/ L ; NR, 790/ L ; P 0.15 .
In a multivariate analysis, the following factors were signi cantly associated with OS : ECOG performance status P 0.001 , duration of CR1 P 0.007 , time between diagnosis of leukemia and rst GO infusion P 0.01 , monocyte count in the BM P 0.005 , and the number of karyotype abnormalities before GO infusion P 0.002 .
Survival according to ef cacy measures
The median OS was 77 days 391.5 days and 55.5 days for patients with OR and NR, respectively . The OS was signi cantly longer in patients with OR than those with NR P 0.03 ; Figs. 1 and 2 . All the OR patients experienced relapses and the median event-free survival of OR patients was 140 days range, 79-176 days ; Fig. 3 . The causes of death were leukemia, sepsis, and multiple organ failure. GO, gemtuzumab ozogamicin ; OR, overall response ; CR, complete remission ; CRp, CR with incomplete platelet recovery ; NR, no remission ; AML, acute myeloid leukemia ; FAB, FrenchAmerican-British classification ; SWOG, Southwest Oncology Group ; MRC, Medical Research Council ; SCT, stem cell transplantation ; uBMT, unrelated bone marrow transplantation ; CBT, cord blood transplantation ; rBMT, related bone marrow transplantation ; , One patient in whom AML relapsed after uBMT and who received GO as pretherapy prior to CBT is duplicated.
Outcome in patients who received allogeneic stem cell transplantation
Overall, 6 patients received allogeneic stem cell transplantation allo-SCT -5 before GO therapy and 2 after GO therapy ; 1 patient, whose AML relapsed after unrelated BM transplantation and who had received GO as pretherapy prior to cord blood transplantation, underwent allo-SCT both before and after GO therapy. All patients who underwent allo-SCT before or after GO treatment showed NR and died within 91 days of the initial GO infusion. Veno-occlusive disease VOD was not observed in any of these patients. 
Adverse events
Elevation of transaminase and total bilirubin grade 3 was observed in 1 case. In another case, an infusion reaction was observed with a transient decrease in percutaneous oxygen saturation and fever grade 3 . The infusion reaction was resolved with glucocorticoid therapy. BM suppression resulting in neutropenia ≤ 500/ L, grade 4 and thrombocytopenia ≤ 50,000/ L, grade 3 was observed in all patients. Febrile neutropenia occurred in 11 patients 91.7% , while grade 2 nausea and vomiting was observed in 1 patient.
WBC counts and leukemic blasts in PB decreased in all patients after GO infusion. The kinetics of WBC decline after 14 days following the initial GO infusion did not differ signi cantly between OR and NR patients data not shown .
Discussion
In this study we retrospectively evaluated the use of GO in 12 patients and analyzed the factors that affected the outcome of GO therapy. The OR rate for GO monotherapy has been previously reported as 17%-33% 2 , which corresponds with the rate observed in our study 33% . In this study, a signi cant difference was observed between OR and NR patients for factors including OS, ECOG performance status, duration of CR1, time between diagnosis of leukemia and initial GO infusion, number of karyotype abnormalities before GO infusion, cytogenetic risk as defined by the SWOG and MRC classification systems, CD14 expression rate of leukemic blasts in BM, and monocyte count in the BM.
The duration of CR1 was signi cantly longer in OR patients, which was similar to the results of a previous study 7 . Additionally, the time from diagnosis of leukemia to GO infusion was signi cantly longer in OR patients. These ndings suggest that GO therapy is effective in patients who have been previously successfully treated with conventional chemotherapy. Previous studies have reported that P-glycoprotein and multi-drug resistance protein expressions are associated with GO therapy outcomes 1, 4 and conventional chemotherapy outcomes 11 . Thus, we consider sensitivity to conventional chemotherapy an important prognostic factor for GO therapy.
Similar to previous reports, no relationship was observed between the CD33 expression rate on leukemic blasts and the outcome of GO therapy 1, 5, 12 . In our study, a patient patient no. 3 with a CD33 expression rate of 20% achieved CR, while CR has also been reported in a CD33-negative patient 5 . Furthermore, internalization of GO without intermediation by CD33 via endocytosis has been previously demonstrated 13 . These results suggest that it is not possible to predict the effects of GO therapy based on CD33 expression rates alone, and that GO should not be excluded from the therapeutic options even for patients de cient in CD33-positive leukemic cells.
Interestingly, CD33 is known to be expressed on monocytes, and GO-induced apoptosis of monocytes has been previously reported 14, 15 . Van der Velden et al demonstrated that a high CD33-antigen load in PB is an independent adverse prognostic factor, likely due to peripheral consumption of GO 6 . In our study, the CD14 expression rate and monocyte count in the BM were signi cantly lower in the OR group as compared to the NR group.
Additionally, the monocyte count in the BM was signi cantly associated with OS in a multivariate analysis. However, there are no reports regarding an association between monocyte count or CD14 expression rate and GO therapy outcomes. The reason why GO therapy failed in patients with high monocyte counts is not clear. Further studies are needed to clarify the association between monocyte counts and GO therapy outcomes.
In our study, both the number of karyotype abnormalities and the SWOG/MRC cytogenetic risk were signi cantly different between NR and OR patients before GO infusion, which support a previous study reporting an association between MRC cytogenetic risk and clinical outcomes of GO therapy 7 . These ndings suggest that the number of karyotype abnormalities and cytogenetic risk are predictive factors for GO therapy outcomes.
In classical AML treatment, older patients are known to have poorer outcomes than younger patients 16 . However, a previous study has demonstrated that GO is well-tolerated by elderly patients aged ≥ 60 years 16 ; moreover, no signi cant difference has been observed in the OR rate of GO therapy between patients aged 60 and ≥ 60 years 7 . For patients
